Jan 2021
10:57pm, 28 Jan 2021
7,499 posts
|
sallykate
I’m on the Novavax trial; I think that if they’ve reached that endpoint they’ll unblind the results and let us all know whether we were in the placebo or the intervention arm. Good to hear it’s successful.
|
Jan 2021
11:04pm, 28 Jan 2021
4,668 posts
|
run free
Do you have snow?
|
Jan 2021
11:05pm, 28 Jan 2021
4,669 posts
|
run free
(meant for Tim)
|
Jan 2021
11:18pm, 28 Jan 2021
3,250 posts
|
Tim of Fife
The town that I live in seldom if ever has real snow. Today, was that awful heavy and fine drizzle
|
Jan 2021
12:06am, 29 Jan 2021
1,948 posts
|
Grast_girl
Novavax was the one the experts in these things were saying they'd choose out of the front runners. Can't remember why at the moment, but I'm sure twitter will provide.
|
Jan 2021
6:25am, 29 Jan 2021
22,746 posts
|
EvilPixie
Twice this week hospital have called mum to a heart consultation
Twice she’s declined as she won’t go anywhere without having had a vaccine
She should be seen 6mthly and it’s all most 12 since her last appointment
|
Jan 2021
6:55am, 29 Jan 2021
4,234 posts
|
Little Miss Happy
At least that sounds as though she's decided she will have the vaccine EP.
|
Jan 2021
7:48am, 29 Jan 2021
24,669 posts
|
Johnny Blaze
"Novavax’s investigational vaccine, NVX-CoV2373, is made from a stabilized form of the coronavirus spike protein using the company’s recombinant protein nanoparticle technology. The purified protein antigens in the vaccine cannot replicate and cannot cause COVID-19. The vaccine also contains a proprietary adjuvant, MatrixM™. Adjuvants are additives that enhance desired immune system responses to vaccine. NVX-CoV2373 is administered in liquid form and can be stored, handled and distributed at above-freezing temperatures (35° to 46°F). A single vaccine dose contains 5 micrograms (mcg) of protein and 50 mcg of adjuvant.
In animal tests, NVX-CoV2373 vaccination produced antibodies that blocked the coronavirus spike protein from binding to the cell surface receptors targeted by the virus, preventing viral infection. In results(link is external) of a Phase 1 clinical trial published in the New England Journal of Medicine, NVX-CoV2373 was generally well-tolerated and elicited higher levels of antibodies than those seen in blood samples drawn from people who had recovered from clinically significant COVID-19. NVX-CoV2373 also is being evaluated in a Phase 2b trial in South Africa, now fully enrolled with 4,422 volunteers, and data from a Phase 1/2 continuation trial in the United States and Australia is expected as early as first quarter 2021. Novavax also recently completed enrollment of more than 15,000 volunteers in a Phase 3 trial of the candidate vaccine in the United Kingdom, which is also testing two injections of 5 mcg of protein and 50 mcg of Matrix-M adjuvant administered 21 days apart."
Sounds super-clever!
|
Jan 2021
7:52am, 29 Jan 2021
22,747 posts
|
EvilPixie
True LMH
But she wants the 1st appointment of the day so less people will have been there!
|
Jan 2021
8:43am, 29 Jan 2021
1,680 posts
|
Roberto
Had a very slight ache in my arm when I woke up at 4am. But when I woke up again at 7, feel absolutely fine. Havent heard from my manager or colleague yet about how they are doing. All had AZ yesterday.
Newcastle Centre of Life really was well organised. But it was incredibly quiet. I was in the observation area after, and the St John's ambulance staff were talking to each other about how there was noone at all in the screening/vaccination area.
|